Abstract
Tumor vascularisation, the formation of blood vessels is a central process to allow tumor growth beyond limited sizes and to facilitate metastasis formation. Angiogenesis is regulated by a balance of stimulatory and inhibitory factors. Angiogenic factors have been the focus of intense research since the prospects of new therapeutic approaches seemed enormous. Vascular endothelial growth factor (VEGF) has emerged as the most potent and most specific growth factor for endothelial cells and therefore a relevant target for novel anticancer therapy. A wide range of agents have been designed for their ability to interfere the VEGF signalling pathway. In addition, several drugs are currently in advanced clinical development. This review describes the current experimental strategies to inhibit VEGF and will also summarize and discuss the results of recent clinical trials involving anti-VEGF compounds either as standalone therapy or in combination with chemotherapy in lung cancer.
Keywords: Lung cancer therapy, VEGF, antiangiogenesis
Current Medicinal Chemistry
Title: Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches
Volume: 14 Issue: 30
Author(s): H. Kuhn, S. Hammerschmidt and H. Wirtz
Affiliation:
Keywords: Lung cancer therapy, VEGF, antiangiogenesis
Abstract: Tumor vascularisation, the formation of blood vessels is a central process to allow tumor growth beyond limited sizes and to facilitate metastasis formation. Angiogenesis is regulated by a balance of stimulatory and inhibitory factors. Angiogenic factors have been the focus of intense research since the prospects of new therapeutic approaches seemed enormous. Vascular endothelial growth factor (VEGF) has emerged as the most potent and most specific growth factor for endothelial cells and therefore a relevant target for novel anticancer therapy. A wide range of agents have been designed for their ability to interfere the VEGF signalling pathway. In addition, several drugs are currently in advanced clinical development. This review describes the current experimental strategies to inhibit VEGF and will also summarize and discuss the results of recent clinical trials involving anti-VEGF compounds either as standalone therapy or in combination with chemotherapy in lung cancer.
Export Options
About this article
Cite this article as:
Kuhn H., Hammerschmidt S. and Wirtz H., Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches, Current Medicinal Chemistry 2007; 14 (30) . https://dx.doi.org/10.2174/092986707782793907
DOI https://dx.doi.org/10.2174/092986707782793907 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Flow Shear Induced Changes in Membrane Fluidity: Dependence on Cell- Substrate Adhesion Strength
Current Analytical Chemistry Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis
Current Gene Therapy Efficacy and Toxicological Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Subject Index To Volume 4
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry